MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients

Table 1 Demographic data

		MOG-IgG	AQP4-IgG	MOG-IgG vs. AQP4-IgG (MWU/Chi²)
		MOG-IgG	AQP4-IgG	p
Patients	N	16	16
Age (years)	Mean ± SD	44.0 ± 15.2	43.2 ± 13.9	0.838
Sex (f/m)		15/1	16/0	>0.999
Ophthalmologic comorbidities	N	2^a) (13 %)	0 (0 %)
Age at onset (years)	Mean ± SD	37.2 ± 15.1	34.7 ± 14.8	0.669
Time since onset (years)	Mean ± SD	6.9 ± 6.5	8.4 ± 6.8	0.287
ON eyes	N (%)	29 (91.6 %)	25 (78.1 %)
Number of ON episodes	Median (range)	4.5 (1–13)	2 (1-4)	0.012
Myelitis prevalence	N (%)	8 (50 %)	15 (93.8 %)	0.018
ARR	Median (range)	1.25 (0.38–7.14)	0.64 (0.17–1.44)	0.026
ON ARR	Median (range)	0.69 (0.17–7.14)	0.29 (0.07–0.96)	0.004
EDSS	Median (range)	3.0 (1.0–7.5)	4.0 (1.0–6.5)	0.064

Abbreviations: AQP4-IgG aquaporin-4 antibody-seropositive NMOSD patients, ARR annualized relapse rate, EDSS expanded disability status scale, f female, m male, MOG-IgG myelin oligodendrocyte glycoprotein antibody-seropositive patients, MWU Wilcoxon-Mann-Whitney U test, ON optic neuritis, SD standard deviation
^a)Early stage dry macular degeneration in both eyes and suspect for early stage glaucoma, respectively
p-values in bold emphasis depict significant values (p < 0.05)

ISSN: 1742-2094